Topotecan and Melphalan for Retinoblastoma

NCT04799002 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-sen University

Phase

Phase 3

Started

2021-03-11

Last updated

2021-03-16

Condition(s) studied

RetinoblastomaChemotherapy Effect

Investigational drug(s) / intervention(s)

TopotecanMelphalan

Topotecan: Topotecan intraocular injection for chemotherapy in retinoblastoma

Melphalan: Melphalan intraocular injection for chemotherapy in retinoblastoma

Study summary

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * diagnosed as retinoblastoma * receiving eyeball-sparing treatment Exclusion Criteria: * disease progression during follow-up

Primary outcome measure(s)

Eyeball-sparing rate — 5 years after chemotherapy
Eyeball-sparing rate during chemotherapy in retinoblastoma patients

Trial sites (1)

Facility	City	Region	Status
Sun Yat-sen University	Guangzhou	Guangdong	Recruiting

More Sun Yat-sen University trials in China

SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx Recruiting

Esthetic, Clinical and Radiographic Outcomes of Immediate and Delayed Implant Placement Recruiting

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns Recruiting

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial Recruiting

Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment. Active, not recruiting

Other trials for the same condition

High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed Recruiting

Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC Recruiting

S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma Recruiting

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer Recruiting

Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04799002 on ClinicalTrials.gov ↗ ← All trials in China